I am pleased to share a deeper look into my professional journey and the experiences that have shaped my career across global drug discovery, biotechnology, and scientific leadership. Over the past several decades, I’ve had the privilege of contributing to meaningful research, guiding innovative teams, and supporting the growth of emerging therapeutic programs around the world. Here is my biography.

I’m excited to share a deeper look into my professional journey across food safety, regulatory science, analytical chemistry, and industry leadership. From leading research collaborations with the FDA to guiding scientific strategy at Starbucks and now serving as Executive Director of IFSH at Illinois Tech, my career has been driven by a passion for advancing public health through science and integrity. Here is my biography.

Dr. Trudy Vanhove is a seasoned biopharmaceutical executive and venture partner with nearly 30 years of experience leading drug development, regulatory strategy, and corporate growth across biotech and pharmaceutical companies. She has played a pivotal role in launching multiple FDA- and EMA-approved therapies and has a strong track record in building high-performing teams, driving strategic partnerships, and supporting financing efforts. Fluent in several languages and with extensive international experience, Dr. Vanhove brings a unique global perspective and a deep scientific and business acumen to board roles and investment opportunities in the biotech sector.

I'm excited to share my professional biography, which reflects my journey through five decades of innovation in the chemical and oilfield industries. From leading groundbreaking R&D efforts to securing 73 U.S. patents and mentoring teams across sectors, it's been a rewarding path of discovery and contribution. I’m passionate about applying my experience to solve real-world problems and support forward-thinking organizations.

Dr. Gilles Besin is a visionary scientific executive whose career spans over 20 years at the forefront of RNA therapeutics and immunology. As Chief Scientific Officer at Orbital Therapeutics, he is redefining the landscape of next-generation RNA medicine through groundbreaking work in mRNA and circular RNA platforms. From leading vaccine development programs to spearheading major biotech acquisitions, Dr. Besin blends deep scientific expertise with strategic insight, positioning him as a driving force in translating cutting-edge research into real-world therapeutic solutions.

Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Dr. Chandra Shekhar Mishra is a distinguished scientist and technology strategist with over 35 years of expertise in high-energy physics, AI-driven research, and accelerator technology. Renowned for his leadership in large-scale scientific projects, he has played a pivotal role in advancing AI applications for data science, fostering international collaborations, and securing multi-million-dollar research initiatives. As a key architect of the US-India strategic partnership in accelerator technology, he successfully facilitated a $200 million agreement between the U.S. Department of Energy and India’s Department of Atomic Energy. With over 300 scientific publications and extensive experience in governance, strategic planning, and global negotiations, Dr. Mishra continues to drive innovation at the intersection of AI, energy, and high-tech industries. Now seeking board and advisory roles, he aims to leverage his expertise to help organizations accelerate technological breakthroughs, build strategic partnerships, and navigate complex industry challenges.